AI Is Reading 15 Million X-Rays a Year With No Human in the Loop | Prashant Warier, Qure.ai
Episode
41 min
Read time
2 min
Topics
Productivity, Health & Wellness, Relationships
AI-Generated Summary
Key Takeaways
- ✓Autonomous TB Screening: Qure.ai operates with zero human radiologists in the loop for tuberculosis screening across 70-75 countries, processing 15 million X-rays annually. WHO explicitly endorsed Qure's algorithm for autonomous chest X-ray interpretation in 2021. When a scan flags positive, patients proceed directly to sputum testing within 20 seconds of upload.
- ✓Lung Nodule Malignancy Scoring: The CREATE study validated Qure's lung nodule malignancy risk score against routine chest X-rays. Of 100 patients flagged high-risk, 54 confirmed positive on CT scan — compared to only 2 positives per 100 in standard CT screening programs. Sensitivity exceeded 95%, with zero false-negative cancer cases recorded.
- ✓Early Detection Stage Shift: Qure's lung cancer pathway, deployed across 700-800 centers globally, targets shifting diagnosis from 80% late-stage to a 50/50 early-to-late ratio. The system detects nodules on routine X-rays taken for unrelated reasons, enabling prescreening without requiring dedicated low-dose CT screening appointments or patient compliance with separate programs.
- ✓Regulatory Pathway as Market Entry: Qure holds 26 FDA clearances, 65 CE-marked findings in Europe, and clearance across 105 countries. Each product is classified as a Software as a Medical Device, requiring clinical publications — currently 200+ — to demonstrate efficacy. Health systems evaluating AI radiology tools should verify this regulatory and evidence trail before deployment.
- ✓EMR Plus Imaging Integration: Qure's diagnostic value compounds when imaging AI connects to electronic medical records. Integration with both PACS and EMR systems takes several months per deployment but enables combined predictions unavailable from imaging alone. Health systems can contact Qure at partner@qure.ai; a provider directory is planned for the Qure.ai website.
What It Covers
Prashant Warier, CEO of Qure.ai, explains how his company's medical imaging AI processes 15 million chest X-rays annually across 105 countries, detects lung cancer nodules 60+ days earlier than standard protocols, and operates fully autonomously for tuberculosis screening where no radiologists exist.
Key Questions Answered
- •Autonomous TB Screening: Qure.ai operates with zero human radiologists in the loop for tuberculosis screening across 70-75 countries, processing 15 million X-rays annually. WHO explicitly endorsed Qure's algorithm for autonomous chest X-ray interpretation in 2021. When a scan flags positive, patients proceed directly to sputum testing within 20 seconds of upload.
- •Lung Nodule Malignancy Scoring: The CREATE study validated Qure's lung nodule malignancy risk score against routine chest X-rays. Of 100 patients flagged high-risk, 54 confirmed positive on CT scan — compared to only 2 positives per 100 in standard CT screening programs. Sensitivity exceeded 95%, with zero false-negative cancer cases recorded.
- •Early Detection Stage Shift: Qure's lung cancer pathway, deployed across 700-800 centers globally, targets shifting diagnosis from 80% late-stage to a 50/50 early-to-late ratio. The system detects nodules on routine X-rays taken for unrelated reasons, enabling prescreening without requiring dedicated low-dose CT screening appointments or patient compliance with separate programs.
- •Regulatory Pathway as Market Entry: Qure holds 26 FDA clearances, 65 CE-marked findings in Europe, and clearance across 105 countries. Each product is classified as a Software as a Medical Device, requiring clinical publications — currently 200+ — to demonstrate efficacy. Health systems evaluating AI radiology tools should verify this regulatory and evidence trail before deployment.
- •EMR Plus Imaging Integration: Qure's diagnostic value compounds when imaging AI connects to electronic medical records. Integration with both PACS and EMR systems takes several months per deployment but enables combined predictions unavailable from imaging alone. Health systems can contact Qure at partner@qure.ai; a provider directory is planned for the Qure.ai website.
Notable Moment
Warier describes primary care becoming predominantly AI-driven within five to ten years — not as a distant possibility but as a near-certain trajectory. The first clinical interaction a patient has will likely be with an AI system before any human physician becomes involved in the process.
Episode Transcript
Is the doctor's office of the future going to be a bunch of these systems, and the doctor kind of guides you? The AI gives the doctor a cheat sheet on what he should pay attention to. You go in and get a body scan. The doctor gets a report of what he should pay attention to. Is health care moving in that direction? My personal belief is that primary care will be AI in the future, maybe five to ten years from now. We have to be more proactive about diagnostics, and we'll see algorithms play a role in that. I think that where definitely the world is headed, where diagnostics will happen much earlier to the amount of data that we are generating. And AI has a big role to play in that journey. So let's start with with you introducing yourself to listeners. Hi. My name is Prashant Warriar. I'm the cofounder and CEO of Cure. I've been, building AI algorithms for the last twenty five years. I did a bachelor's, in technology out of, in engineering out of India from one of the IITs, IIT Delhi, and, went to The, US Georgia Tech did a PhD in operations research. My PhD was optimizing trucking networks for for the for US, trucking organizations and, spent, I mean, did that, went on to work for SAP where I was, basically doing price optimization for retail, so price optimization, markdown optimization, demand forecasting, a bunch of retail and consumer products problems. This was all in The US. I came back to India, about fourteen years ago and, set up an advertising technology startup, which was using AI to, to basically collect consumer behavior from a lot of ecommerce sites in India and then use that to target the right ads, for customers. And, then, that, got an exit for that about ten years ago and started Cure, slightly less than ten years ago focused on AI, in the health care space. And, we'd be yeah. We'll talk about the Cure journey today. Yep. And and so talk about what CureAI was founded to do and how it has evolved. So we when we started, our hypothesis was that, that image recognition algorithms, I mean, this there's Alex network that was one of these neural convolutional networks that was released in 2012. Right? And, our hypothesis was that can we sort of take some of those techniques, apply it to a lot of radiology images, billions of them, and Right. Would that enable us to then identify abnormalities on a X-ray or a CT scan? And that was the hypothesis when we started. And, of course, I mean, we we did that. Spent a lot of time collecting data because getting access to anonymized, the identified customer data, patient data is not easy. And, so spent almost the first year, just working with hospital systems, especially we started out of India. So working with hospital systems in India, getting, de …
Get the full transcript (6,805 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 38-minute episode.
Get Eye on AI summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Eye on AI
AI Agents Fixing Your IT Before You Even Know Something Broke | Erhan Giral & Ryan Manning, BMC Helix
Aug 3 · 59 min
Latent Space
Giving Agents Computers — Ivan Burazin, Daytona
May 21
More from Eye on AI
"According to NASA's Definition of Life, I'm Not Alive" - Why Nobody Can Define Life | Dr. Kate Adamala
Jul 29 · 46 min
Beyond Biotech
Argobio: the venture model building Europe’s next biotech champions
Apr 17
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links.
company
“Prashant Warier, CEO of Qure.ai, explains how his company's medical imaging AI processes 15 million chest X-rays annually across 105 countries, detects lung cancer nodules 60+ days earlier than standard protocols, and operates fully autonomously for tuberculosis screening where no radiologists exist.”
other
“The CREATE study validated Qure's lung nodule malignancy risk score against routine chest X-rays.”
More from Eye on AI
We summarize every new episode. Want them in your inbox?
AI Agents Fixing Your IT Before You Even Know Something Broke | Erhan Giral & Ryan Manning, BMC Helix
"According to NASA's Definition of Life, I'm Not Alive" - Why Nobody Can Define Life | Dr. Kate Adamala
"According to NASA's Definition of Life, I'm Not Alive" - Why Nobody Can Define Life | Dr. Kate Adamala
6 in 10 Enterprises Can't Find the Root Cause When Their AI Workloads Fail | Paul Appleby, Virtana
Inside the Enterprise Browser Rebuilding Security for the AI Era | Bradon Rogers, Island
Similar Episodes
Related episodes from other podcasts
Latent Space
May 21
Giving Agents Computers — Ivan Burazin, Daytona
Beyond Biotech
Apr 17
Argobio: the venture model building Europe’s next biotech champions
NVIDIA AI Podcast
Feb 27
AI Agents and the Future of Global Trade with Alibaba’s Kuo Zhang - Ep. 291
Decoder
Feb 9
Siemens CEO's mission to automate everything
Decoder
Feb 2
Docusign's CEO on the dangers of trusting AI to read, and write, your contracts
Explore Related Topics
This podcast is featured in Best AI Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Eye on AI.
Every Monday, we deliver AI summaries of the latest episodes from Eye on AI and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime